Individual Submission Summary
Share...

Direct link:

Impact of Opioid Medication for Opioid use Disorder on Maternal Behavior and Offspring Outcome: What we can Learn from Translational Rodent Models

Fri, March 24, 3:30 to 5:00pm, Salt Palace Convention Center, Floor: 3, Meeting Room 355 E

Abstract

The current opioid epidemic has led to a drastic increase in pregnant women being exposed to opioids. This includes opioid medication for opioid use disorders (MOUDs, e.g., buprenorphine (BUP) or methadone) to combat negative effects of misused opioids on the mother and developing offspring. BUP is a semi-synthetic opioid with unique affinities at various opioid receptors. It is a partial agonist at the mu-receptor and an antagonist at the kappa- and delta opioid receptor and it has been shown to produce better infant outcomes after gestational treatment compared to methadone or misused opioids. Endogenous opioids play a significant role in orchestrating neuronal adaptations within the maternal brain network (MBN) for the successful ‘switch’ from a nulliparous brain to a maternal brain to incentivize nurturing maternal behaviors from the dam. Therefore, it is not surprising that exogenous opioid exposure during gestation can disrupt maternal care and impact offspring development, However, effects of BUP on the long-term outcome of the offspring or on the maternal brain while transitioning to motherhood are not well understood. We implemented a translational rodent model to mimic chronic opioid (mis)use (morphine exposure, 3-7mg/kg/day s.c.) or maintenance opioid drug use (buprenorphine exposure, 0.3mg-1mg/kg/day s.c.) to investigate the behavioral and neurochemical consequences of gestational opioid exposure on dams and their offspring. Opioid or saline administration to females began prior to pregnancy and was either continued until postpartum day 2 or discontinued shortly before parturition on gestational day 19 to test whether removing the drug before birth would rescue adverse effects. Our results show that even a low dose of BUP decreased maternal care, delayed offspring development, and decreased offspring body weight gain and pain sensitivity later in life. Importantly, a high dose of BUP drastically reduced maternal care and offspring survival, and this was not rescued by BUP discontinuation on gestational day 19. On the other hand, both continued and discontinued morphine exposure seemed to result in fewer deficits in maternal behavior as compared to buprenorphine. Overall, our results suggest, that gestational exposure to BUP may inhibit the neuronal ‘switch’ from aversive to rewarding perception of pups in rat dams, subsequently influencing offspring survival. More research is essential to understand how buprenorphine interacts with the maternal brain network during the transition to motherhood to help avoid possible negative consequences on maternal care, the maternal brain and compounded effects on opioid-exposed offspring.

Author